Cytogen deal

CYTO and Imperial Cancer Research Fund of the U.K. (ICRF) jointly will develop monoclonal antibody conjugate products to diagnose cancers. The two-year collaboration began in February, but CYTO delayed an announcement because of its corporate restructuring.

Under the agreement, CYTO is providing an undisclosed amount of funding for imaging studies in breast, ovarian and prostate cancer at the ICRF's nuclear medicine group in London. Several of the antibodies, originally developed by ICRF, were acquired by CYTO from Unipath Ltd. earlier this year. ...